China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
BURLINGAME, Calif., Nov. 01, 2016 -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that management will present at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, November 8 at 10:30 a.m. MT in Scottsdale, Arizona.
A webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the conference website or on the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s TECENTRIQ® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Investor Contact: Jason Coloma, Ph.D. SVP and Chief Business Officer 650-900-4511 [email protected] Media Contact: Julie Normart, W2O Group 415-946-1087 [email protected]
